Please login to the form below

Not currently logged in
Email:
Password:

Phase 3 failure

This page shows the latest Phase 3 failure news and features for those working in and with pharma, biotech and healthcare.

Boehringer Ingelheim/Lilly’s empagliflozin is first drug to show clear benefit in heart failure

Boehringer Ingelheim/Lilly’s empagliflozin is first drug to show clear benefit in heart failure

Results presented at the European Society of Cardiology Congress from the phase 3 trial demonstrated a 27% drop in hospitalisation risk. ... Results from the phase 3 EMPEROR-Preserved trial were presented on 27 August 2021 at the European Society of

Latest news

More from news
Approximately 1 fully matching, plus 11 partially matching documents found.

Latest Intelligence

  • Pharma deals during November 2013 Pharma deals during November 2013

    This antibiotic kills Pseudomonas aeruginosa by a novel mechanism of action and has completed its phase 1 development. ... It was just under a year since the report that the phase 3 study had ended in failure, leading GSK to give up the co-development

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Jet Off with Maloff Protect

Latest intelligence

Our Top 5 Pharma Picks From Cannes Lions
Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
The Evolving Role of the Sales Rep
The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
Measure your omnichannel maturity with our new tool
Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....